SEARCH:   Advanced

Blood, 1 October 2005, Vol. 106, No. 7, pp. 2424-2432. Prepublished online as a Blood First Edition Paper on June 23, 2005; DOI 10.1182/blood-2005-01-0342. This Article Full Text Full Text (PDF) Supplemental Figures All Versions of this Article: 2005-01-0342v1 106/7/2424    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gunzer, M. Articles by Grabbe, S. Search for Related Content PubMed PubMed Citation Articles by Gunzer, M. Articles by Grabbe, S. Related Collections Immunobiology Phagocytes Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion Matthias Gunzer, Helge Riemann, Yasmin Basoglu, Anja Hillmer, Carsten Weishaupt, Sandra Balkow, Bernd Benninghoff, Beat Ernst, Meike Steinert, Thomas Scholzen, Cord Sunderkötter, and Stephan Grabbe From the German Research Centre for Biotechnology, Braunschweig, Germany; Department of Dermatology, University of Münster, Germany; 3M Medica, Neuss, Germany; University of Basel Institute of Molecular Pharmacy, Switzerland; and Department of Dermatology, University of Essen, Germany. Toll-like receptor (TLR) ligands lead to the induction of proinflammatory cytokines and are potent enhancers of specific immune responses. We show here that a single systemic dose of R-848, a ligand for TLR7, potently enhanced hapten sensitization during the induction of contact hypersensitivity (CHS). However, R-848 administration also resulted in a rapid and almost complete depletion of leukocytes from the blood. This effect was transient and was associated with general induction of endothelial adhesiveness. In response to R-848, endothelial cells up-regulated adhesion molecules in vitro and in vivo and leukocytes exhibited increased rolling on endothelia in R-848-treated animals. Adhesion molecule induction appeared to be a direct effect, because endothelial cells expressed TLR7 in vitro and in vivo. After R-848 treatment, the tissue residence time of leukocytes was markedly prolonged in all major peripheral organs. The resulting transiently reduced availability of peripheral-blood leukocytes (PBLs) (TRAP) significantly inhibited otherwise potent CHS responses until the effector cells returned. Thus, although TLR7 ligands are effective adjuvants for the induction of cell-mediated immunity, they can transiently inhibit the elicitation of localized immune responses, possibly due to a systemic endothelial activation throughout the vasculature. (Blood. 2005;106:2424-2432) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Baenziger, M. Heikenwalder, P. Johansen, E. Schlaepfer, U. Hofer, R. C. Miller, S. Diemand, K. Honda, T. M. Kundig, A. Aguzzi, et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology Blood, January 8, 2009; 113(2): 377 - 388. [Abstract] [Full Text] [PDF] E. L. J. M. Smits, P. Ponsaerts, Z. N. Berneman, and V. F. I. Van Tendeloo The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy Oncologist, August 1, 2008; 13(8): 859 - 875. [Abstract] [Full Text] [PDF] N. B. Butchi, S. Pourciau, M. Du, T. W. Morgan, and K. E. Peterson Analysis of the Neuroinflammatory Response to TLR7 Stimulation in the Brain: Comparison of Multiple TLR7 and/or TLR8 Agonists J. Immunol., June 1, 2008; 180(11): 7604 - 7612. [Abstract] [Full Text] [PDF] A. Z. Dudek, C. Yunis, L. I. Harrison, S. Kumar, R. Hawkinson, S. Cooley, J. P. Vasilakos, K. S. Gorski, and J. S. Miller First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7119 - 7125. [Abstract] [Full Text] [PDF] P. Reichardt, B. Dornbach, S. Rong, S. Beissert, F. Gueler, K. Loser, and M. Gunzer Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse Blood, September 1, 2007; 110(5): 1519 - 1529. [Abstract] [Full Text] [PDF] L. I. Harrison, C. Astry, S. Kumar, and C. Yunis Pharmacokinetics of 852A, an Imidazoquinoline Toll-Like Receptor 7-Specific Agonist, Following Intravenous, Subcutaneous, and Oral Administrations in Humans J. Clin. Pharmacol., August 1, 2007; 47(8): 962 - 969. [Abstract] [Full Text] [PDF] E. Kamphuis, T. Junt, Z. Waibler, R. Forster, and U. Kalinke Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia Blood, November 15, 2006; 108(10): 3253 - 3261. [Abstract] [Full Text] [PDF] J. Heidemann, W. Domschke, T. Kucharzik, and C. Maaser Intestinal microvascular endothelium and innate immunity in inflammatory bowel disease: a second line of defense? Infect. Immun., October 1, 2006; 74(10): 5425 - 5432. [Full Text] [PDF] R. Chakraverty, D. Cote, J. Buchli, P. Cotter, R. Hsu, G. Zhao, T. Sachs, C. M. Pitsillides, R. Bronson, T. Means, et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues J. Exp. Med., August 7, 2006; 203(8): 2021 - 2031. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020